FSD Pharma (HUGE) Stock Analysis

What FSD Pharma does

FSD Pharma Inc. is a biopharmaceutical research and development company, operating through its various subsidiaries. The firm's leading drug candidate, FSD-201, is currently undergoing Phase II clinical trials for the treatment of COVID-19 disease. Additionally, FSD Pharma is actively developing Lucid-PSYCH, a psychoactive molecule identified for its potential in addressing neuropsychiatric conditions such as depressive disorder. They are also advancing Lucid-MS, a proprietary new chemical entity which, in preclinical models, has demonstrated the capacity to prevent and reverse myelin degradation—the fundamental mechanism behind multiple sclerosis. Established in 1998, FSD Pharma Inc. is headquartered in Toronto, Canada.

Key metrics

ETFs linked to HUGE

Broad-market and Healthcare sector ETFs an investor holding FSD Pharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how HUGE fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for FSD Pharma?

FSD Pharma trades under the ticker HUGE on NASDAQ.

Which exchange is HUGE listed on?

HUGE is listed on NASDAQ.

What sector does FSD Pharma operate in?

FSD Pharma is classified in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).

How can PortView help analyze HUGE in a portfolio?

PortView shows HUGE's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.